Literature DB >> 7585655

Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation.

O Katoh1, H Tauchi, K Kawaishi, A Kimura, Y Satow.   

Abstract

Vascular endothelial growth factor (VEGF) has been identified as a peptide growth factor specific for vascular endothelial cells. In this study, we demonstrated the expression of the KDR gene transcript, which encodes a cell surface receptor for VEGF, in normal human hematopoietic stem cells, megakaryocytes, and platelets as well as in human leukemia cell lines, HEL and CMK86. Moreover, we showed the expression of VEGF gene transcript in these normal fresh cells and cell lines. To elucidate biological functions of VEGF on hematopoiesis, we determined whether this growth factor has mitogenic activity to hematopoietic cells or the ability to suppress apoptotic cell death. The liquid culture and colony-formation assay revealed that VEGF suppressed apoptotic cell death of both CMK86 cells and normal hematopoietic stem cells caused by gamma-ray irradiation, although mitogenic activity of VEGF was not detected. The ability of VEGF to suppress apoptotic cell death was independent of the change of cell cycle distribution. These data suggest that VEGF may play an important role in survival or maintenance of hematopoietic stem cells due to the prevention of apoptotic cell death caused by some stresses such as ionizing radiation and that VEGF may give leukemia cells some abilities of resistance against radiotherapy in an autocrine or paracrine manner.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7585655

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  60 in total

1.  Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization.

Authors:  T Murohara; H Ikeda; J Duan; S Shintani; K i Sasaki; H Eguchi; I Onitsuka; K Matsui; T Imaizumi
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

Review 2.  Angiogenesis in hematologic malignancies and its clinical implications.

Authors:  Renchi Yang; Zhong Chao Han
Journal:  Int J Hematol       Date:  2002-04       Impact factor: 2.490

Review 3.  Role of vascular permeability factor/vascular endothelial growth factor in eye disease.

Authors:  R O Schlingemann; V W van Hinsbergh
Journal:  Br J Ophthalmol       Date:  1997-06       Impact factor: 4.638

4.  Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in normal and atherosclerotic human arteries.

Authors:  T Couffinhal; M Kearney; B Witzenbichler; D Chen; T Murohara; D W Losordo; J Symes; J M Isner
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

Review 5.  VEGF as a mediator of tumor-associated immunodeficiency.

Authors:  J E Ohm; D P Carbone
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

6.  Soluble vascular endothelial growth factor decoy receptor FP3 exerts potent antiangiogenic effects.

Authors:  De-Chao Yu; Jung-Sun Lee; Ji Young Yoo; Hyewon Shin; Hongxin Deng; Yuquan Wei; Chae-Ok Yun
Journal:  Mol Ther       Date:  2012-01-24       Impact factor: 11.454

7.  GM-CSF and IL-4 Fusion Cytokine Induces B Cell-Dependent Hematopoietic Regeneration.

Authors:  Jiusheng Deng; Yanqiu Li; Andrea Pennati; Shala Yuan; Jian Hui Wu; Edmund K Waller; Jacques Galipeau
Journal:  Mol Ther       Date:  2017-02-01       Impact factor: 11.454

Review 8.  Adverse effects of anticancer agents that target the VEGF pathway.

Authors:  Helen X Chen; Jessica N Cleck
Journal:  Nat Rev Clin Oncol       Date:  2009-07-07       Impact factor: 66.675

9.  Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets.

Authors:  R Möhle; D Green; M A Moore; R L Nachman; S Rafii
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-21       Impact factor: 11.205

10.  Generation of CD34+ cells from human embryonic stem cells using a clinically applicable methodology and engraftment in the fetal sheep model.

Authors:  Jaehyup Kim; Esmail D Zanjani; Christine M Jeanblanc; A Daisy Goodrich; Peiman Hematti
Journal:  Exp Hematol       Date:  2013-04-20       Impact factor: 3.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.